BioWa, Lonza sign deal with Pfizer for antibody development

08/1/2013 | Pharmaceutical Business Review Online

Lonza and BioWa have granted Pfizer the right to use their Potelligent CHOK1SV cell line technology in the research and development of antibodies. The Potelligent CHOK1SV cell line can be used to develop antibodies that function in whole blood and have cytotoxic effects even at low antigen levels.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD